Get the Stockscreener App
7.75
4.44%
-0.36
Mersana Therapeutics Inc stock is traded at $7.75, with a volume of 71,593.
It is down -4.44% in the last 24 hours and down -14.76% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$8.11
Open:
$8.16
24h Volume:
71,593
Relative Volume:
0.60
Market Cap:
$38.68M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-0.981
EPS:
-7.9
Net Cash Flow:
$-79.76M
1W Performance:
+8.24%
1M Performance:
-14.76%
6M Performance:
-41.86%
1Y Performance:
-78.01%
1-Day Range:
$7.7101
$8.1932
1-Week Range:
$6.96
$8.1932
52-Week Range:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.75 | 36.83M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Recovery Setup Building in Mersana Therapeutics Inc. Experts Say2025 Valuation Update & Technical Buy Zone Confirmation - thegnnews.com
Sector Leaders Rotate Capital Into Mersana Therapeutics Inc.Trade Risk Assessment & Risk Controlled Stock Pick Alerts - classian.co.kr
How to forecast Mersana Therapeutics Inc. trends using time series2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
Using portfolio simulators with Mersana Therapeutics Inc. includedMarket Sentiment Summary & Risk Controlled Stock Pick Alerts - Newser
How Mersana Therapeutics Inc. stock performs during market volatilityMarket Growth Report & Reliable Entry Point Trade Alerts - Newser
Leerink Partnrs Has Pessimistic View of MRSN Q3 Earnings - Defense World
Will Mersana Therapeutics Inc. outperform the market2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
Will Mersana Therapeutics Inc. benefit from macro trends2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Best data tools to analyze Mersana Therapeutics Inc. stock2025 Trading Volume Trends & Growth-Oriented Investment Plans - Newser
Mersana Therapeutics Inc.’s volatility index tracking explained2025 Big Picture & Capital Efficiency Focused Ideas - Newser
Combining machine learning predictions for Mersana Therapeutics Inc.July 2025 Intraday Action & Growth Focused Entry Point Reports - Newser
Full technical analysis of Mersana Therapeutics Inc. stock - Newser
Combining price and volume data for Mersana Therapeutics Inc.Portfolio Return Report & Precise Trade Entry Recommendations - Newser
Volatility clustering patterns for Mersana Therapeutics Inc.July 2025 Short Interest & Smart Money Movement Alerts - Newser
Guggenheim Cuts Mersana Therapeutics (NASDAQ:MRSN) Price Target to $30.00 - Defense World
Top chart patterns to watch in Mersana Therapeutics Inc.Long Setup & Stepwise Entry and Exit Trade Signals - Newser
Truist Financial Cuts Mersana Therapeutics (NASDAQ:MRSN) Price Target to $36.00 - Defense World
Mersana Therapeutics Inc. stock volume spike explainedPortfolio Risk Summary & Comprehensive Market Scan Reports - Newser
What’s the recovery path for long term holders of Mersana Therapeutics Inc.2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 PreEarnings & Fast Entry High Yield Tips - Newser
Can Mersana Therapeutics Inc. recover in the next quarter2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsPrice Action & Risk Managed Investment Signals - Newser
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone - MSN
Will earnings trigger a reversal in Mersana Therapeutics Inc.Weekly Risk Summary & Weekly Setup with High ROI Potential - Newser
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
How to escape a deep drawdown in Mersana Therapeutics Inc.July 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Automated trading signals detected on Mersana Therapeutics Inc.July 2025 Action & Risk Managed Trade Strategies - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingQuarterly Investment Review & Weekly Hot Stock Watchlists - Newser
Mersana Misses Fiscal Q2 Revenue Target - AOL.com
Chart overlay techniques for tracking Mersana Therapeutics Inc.Trend Reversal & Daily Momentum Trading Reports - Newser
Mersana Therapeutics Inc. Nearing Breakout Level After BounceJuly 2025 PreEarnings & Real-Time Stock Movement Alerts - beatles.ru
Will Mersana Therapeutics Inc. stock go up soonMarket Growth Review & Verified Technical Trade Signals - Newser
Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic - simplywall.st
Mersana Therapeutics Positioned Favorably with Promising Developments and Strategic Adjustments Supporting Buy Rating - TipRanks
Mersana Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana Therapeutics price target adjusted to $36 at Truist after reverse split - MSN
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates - MSN
Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25) - MSN
Truist Securities slashes Mersana stock price target to $36 from $250 - Investing.com Canada
Mersana Therapeutics Q2 2025 Earnings Preview - MSN
Guggenheim Downgrades Mersana Therapeutics to Buy, PT to $30 from $125. - AInvest
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript - Insider Monkey
Guggenheim lowers Mersana stock price target to $30 from $125 By Investing.com - Investing.com Canada
Mersana Therapeutics 2025 Q2 Earnings Slight EPS Improvement Amid Widening Net Loss - AInvest
Mersana Therapeutics Faces Financial Strain Amid U.S. Tariff Uncertainties - TipRanks
Mersana Therapeutics Inc. Bounces Off Moving Average SupportJuly 2025 Update & Expert Curated Trade Setups - beatles.ru
Mersana Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Mersana stock price target raised to $17 from $6 at BTIG - Investing.com Canada
Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics - TipRanks
Mersana Therapeutics (MRSN): Assessing the Path to Value Recovery Amid Clinical Progress and Financial Challenges - AInvest
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mersana Therapeutics Inc Stock (MRSN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):